Biotech firms navigate financial turbulence and strategic deals amid sector-wide shifts. Recursion Pharmaceuticals announced 20% workforce layoffs linked to clinical pipeline cuts after merging with Exscientia, aiming to extend cash runway into mid-2027. National Resilience is closing six manufacturing sites, restructuring to align capacity with demand. MoonLake Immunotherapeutics stock surged following a reported $3B acquisition offer by Merck that was declined. Simultaneously, Odyssey Therapeutics withdrew IPO plans amid a challenging market environment, reflecting ongoing volatility in biotech capital markets.